Search company, investor...
Taysha Gene Therapies company logo

Taysha Gene Therapies

Founded Year



Corporate Minority - P2P | IPO

Total Raised


Market Cap


Stock Price


About Taysha Gene Therapies

Taysha Gene Therapies (NASDAQ: TSHA) seeks to eradicate severe and life-threatening monogenic diseases of the central nervous system (CNS) by advancing its pipeline of 15 AAV (adeno-associated virus) gene therapy programs. It serves clients in the healthcare sector. The firm was founded in 2019 and is based in Dallas, Texas.

Headquarters Location

3000 Pegasus Park Dr. Suite 1430

Dallas, Texas, 75247,

United States


Missing: Taysha Gene Therapies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Taysha Gene Therapies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Taysha Gene Therapies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Taysha Gene Therapies is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Taysha Gene Therapies News

DNA Testing Market to hit $23.04 Bn by 2030, Predicts The Brainy Insights

Nov 16, 2022

GlobeNewswire The demand for DNA testing is anticipated to increase throughout the forecast period as a result of advancements in personalized testing kits. Investments in healthcare and infrastructure have significantly increased in emerging economies like Brazil, India, and China. R&D operations and latest DNA testing technologies are expected to stringent market growth. North America emerged as the largest market for the global DNA testing market, with a 39% share of the market revenue in 2022. Newark, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Brainy Insights estimates that the USD 10 billion in 2022 DNA Testing market will reach USD 23.04 billion by 2030. With a positive growth outlook over the long term, the demand for home DNA testing will experience a steady recovery during the forecast period. The increasing demand for home based DNA testing is expected to increase the demand for DNA testing kits. AD Key Insight of the DNA Testing Market North America to account for the largest market size during the forecast period. North America is expected to have the largest DNA Testing market share. Key factors favouring the growth of the DNA Testing market in North America include the increasing technological advancements in the region. The market growth in the region is also driven by well-developed healthcare infrastructure and favourable government initiatives. The PCR-Based segment is expected to augment the DNA Testing market during the forecast period The PCR-based segment is anticipated to dominate the market over the forecast period. The growth of PCR-based DNA testing is driven by the easy availability of testing kits and reagents capable enough to do basic DNA testing for disease diagnosis. The infectious disease diagnostics segment market size is 2.1 billion in 2022 The infectious disease diagnostics segment held the largest market share in 2022 and is expected to continue during the forecast period, owing to the increasing cases of infectious diseases. Furthermore, the growing number of human infections also increases the demand for infectious disease diagnostics through DNA testing, propelling the segment's growth. DNA Testing Market Scope: Advancement in market In November 2020, The US-based Taysha Gene Therapies and the US-based Invitae health startup joined to assist Invitae's Detect Lysosomal Storage Diseases (Detect LSDs) and Behind the Seizure programmes by providing patients with complimentary genetic testing. In December 2020, Whole-genome sequencing (WGS) will be made available to a select group of Harvard Pilgrim members owing to a risk-sharing arrangement established by Illumina, Inc., a known American genetic testing company, and Harvard Pilgrim Health Care, another significant US-based participant. WGS will be used by the initiative to facilitate a quicker detection of genetic disorders in youngsters. For more information in the analysis of this report, speak to research analyst: Market Dynamics Driver: Growing prevalence of genetic diseases Genetic diseases can result in health issues that are so severe they make living impossible. In the most extreme circumstances, these disorders may result in the miscarriage of the affected embryo or baby. The demand for DNA testing is increasing as hereditary illnesses, and birth abnormalities become more common. Restraint: High Cost DNA testing is costly, which hinders the market's growth. Some health insurance policies may not cover the cost of expensive DNA testing. The various DNA testing prices vary depending on the ailment being tested for. reports that the price of DNA testing for cancer can range from $300 to $5,000. The type of test and its complexity can affect how much a genetic test costs. Opportunity: Rising disposable income Numerous economic and social factors, including the health system's financial arrangements and organizational structure, influence the amount of money a nation spends on healthcare and its growth rate over time. Mainly, there is a significant correlation between a nation's overall income level and the amount of money its citizens spend on health care. Thus, the rising disposable income of people is expected to provide lucrative growth opportunities over the forecast period. AD Challenge: Stringent government regulations There are several stringent government regulations related to DNA Testing. The FDA regulates DNA testing in various ways, some of which necessitate regulatory frameworks as complex as those for Class III medical devices. According to the FDA's final advice, businesses cannot sell a single product with a label that identifies both approved and banned applications. However, according to the FDA, marketing DNA testing equipment with approved/cleared functions and additional activities for which a sponsor does not need permission or clearance is permitted. Interested to Procure The Data? Inquire here at: Some of the major players operating in the DNA Testing market are: Abbott Laboratories Europe (Germany, France, the U.K., Italy, Spain, Rest of Europe) Asia-Pacific (China, Japan, India, Rest of APAC) South America (Brazil and the Rest of South America) The Middle East and Africa (UAE, South Africa, Rest of MEA) Direct purchase a single user copy of the report: About the report: The market is analyzed based on value (USD Billion). All the segments have been analyzed worldwide, regional, and country basis. The study includes the analysis of more than 30 countries for each part. The report analyzes driving factors, opportunities, restraints, and challenges for gaining critical insight into the market. The study includes porter's five forces model, attractiveness analysis, Product analysis, supply, and demand analysis, competitor position grid analysis, distribution, and marketing channels analysis. AD About The Brainy Insights: The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients' objectives of high-quality output within a short span of time. We provide both customized (clients' specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients' requirement whether they are looking to expand or planning to launch a new product in the global market. Contact Us

Taysha Gene Therapies Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Taysha Gene Therapies Rank

Taysha Gene Therapies Frequently Asked Questions (FAQ)

  • When was Taysha Gene Therapies founded?

    Taysha Gene Therapies was founded in 2019.

  • Where is Taysha Gene Therapies's headquarters?

    Taysha Gene Therapies's headquarters is located at 3000 Pegasus Park Dr., Dallas.

  • What is Taysha Gene Therapies's latest funding round?

    Taysha Gene Therapies's latest funding round is Corporate Minority - P2P.

  • How much did Taysha Gene Therapies raise?

    Taysha Gene Therapies raised a total of $125M.

  • Who are the investors of Taysha Gene Therapies?

    Investors of Taysha Gene Therapies include Astellas Pharma, Nolan Capital, PBM Capital Group, Sands Capital, BlackRock and 12 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.